EICOSIS

At EicOsis we are advancing novel, safe and effective oral treatments for patients suffering from pain and inflammation... At EicOsis we are developing a new approach to treat pain and inflammation by inhibiting the soluble Epoxide Hydrolase (sEH), a key regulatory enzyme. Inhibiting sEH increases the levels of naturally occurring anti-inflammatory and pain-relieving compounds. Our first drug candidate is currently undergoing Phase 1 human clinical trials... EicOsis is advancing its first drug candidate to human clinical trials with the support of funding from federal grants and angel investors.

Primary location: Davis United States